Glaxosmithkline Stock News

Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), The Coca-Cola Company (KO) and Adobe Inc. (ADBE).

Immunome (IMNM) gains as FDA lifts clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of COVID-19.

FDA approves AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.

NEW YORK , March 14, 2022 /PRNewswire/ -- Polaris Market Research recently published a research report on "Sleeping Aids Market Share, Size, Trends, Industry Analysis Report, By Product (Mattresses & Pillows, Sleep Laboratories, Medications, Sleep Apnea Devices); By Sleep Disorders; By Region; Segment Forecast, 2022 - 2030" in its research database. According to research report published by Polaris Market Research, the global Sleeping Aids Market size expected to reach to USD 118.31 Billion by 2030 from USD 64.08 Billion in 2021, at a compound annual growth rate (CAGR) of 7.1% during forecast period 2022 to 2030. Report Overview: Sleeping aids products are used in the form of medicines and medical devices to ensure proper monitoring, diagnosis, and treatment for sleep disturbances and disorders. Symptoms of sleep disorders include excessive daytime sleepiness, irregular breathing, or increased movement during sleep. Sleep disorders causes problems with the quality, timing, and amount of sleep, which result in irregular breathing and abnormal sleeping behaviors.

In the latest trading session, GlaxoSmithKline (GSK) closed at $40.56, marking a -0.66% move from the previous day.

According to new research in Australia, some people have developed sotrovimab-resistant mutations following infusions with the GlaxoSmithKline Plc (NYSE: GSK ) and Vir Biotechnology Inc (NASDAQ: VIR ) monoclonal antibody with COVID-19 infection. Data shows that the mutations have been associated with a reduction by a factor of 100 to 297 in neutralization by sotrovimab. "These data show the persistence of viable SARS-CoV-2 in patients … Full story available on Benzinga.com

GlaxoSmithKline (GSK) closed the most recent trading day at $40.83, moving -1.23% from the previous trading session.

The BA.2 sub-variant of Omicron is estimated to make up nearly 12% of all COVID-19 variants circulating in the U.S., the latest genomic surveillance data from the Centers for…

This pharmaceutical company is growing revenue and profits from drugs it doesn't market or sell.

Sanofi with ticker code (SNY) have now 4 analysts covering the stock. The analyst consensus points to a rating of ''Strong_Buy''. The target price ranges between 68.5 and 58 calculating the average target price we see 63.63. Given that the stocks previous close was at 50.18 this indicates there is a potential upside of 26.8%. The 50 day MA is 51.58 while the 200 day moving average is 50.94. The market capitalisation for the company is $121,066m. You can visit the company''s website by visiting: https://www.sanofi.com [stock_market_widget type="chart" template="basic" color="green" assets=SNY" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $153,516m based on the market concensus. Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.

AstraZeneca (AZN) and Sanofi's (SNY) nirsevimab reduces lower respiratory tract infections like bronchiolitis or pneumonia caused by RSV 74.5% in infants.

Vir Bio has a COVID blockbuster in Xevudy, and the stock is super-cheap right now.

Major companies in the pharmaceuticals market include Johnson & Johnson, Novartis AG, Bristol-Myers Squibb, AbbVie, Sanofi S. A, Pfizer Inc. , GlaxosmithKline, F. Hoffmann-La Roche Ltd. , Merck & Co. and AstraZeneca. Major companies in the pharmaceuticals market include Johnson & Johnson, Novartis AG, Bristol-Myers Squibb, AbbVie, Sanofi S. A, Pfizer Inc. , GlaxosmithKline, F. Hoffmann-La Roche Ltd. , Merck & Co. and AstraZeneca.

Major players in the vaccine market are AstraZeneca, Emergent Biosolutions, Glaxosmithkline, Merck, Pfizer, Sanofi Pasteur, Abbott, Astellas Pharma, Bavarian Nordic, CSL Limited, Daiichi Sankyo Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India, Takeda Pharmaceutical Co. Major players in the vaccine market are AstraZeneca, Emergent Biosolutions, Glaxosmithkline, Merck, Pfizer, Sanofi Pasteur, Abbott, Astellas Pharma, Bavarian Nordic, CSL Limited, Daiichi Sankyo Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India, Takeda Pharmaceutical Co.